Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
1. J.P. Morgan upgraded AMRX due to its strong generics business. Crexont’s launch reinforced this view. 2. FDA approved Crexont for Parkinson’s; prescriptions neared 1,000 per week. Growth is evident. 3. Crexont now captures 15% of Rytary’s volume. Revenue projections have risen significantly. 4. AMRX shifted from simple tablets to complex generics. Q4 earnings report and raised target support long-term growth.